Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.48 |
| ▸ | NPY1R | P25929 | 9/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663559 | 0.92 | MAPK8 (0.46) | NPY4RNPY1RNPY5RNPY2RMAPK8 | |
| SCHEMBL29687469 | 0.91 | MAPK8 (0.48) | NPY4RNPY1RNPY5RNPY2RMAPK8 | |
| SCHEMBL30039279 | 0.89 | NPY5R (0.47) | NPY4RNPY1RNPY5RNPY2RMAPK8 | |
| SCHEMBL8720817 | 0.89 | MAPK8 (0.44) | NPY4RNPY1RNPY5RNPY2RMAPK8 | |
| SCHEMBL8720811 | 0.89 | MAPK8 (0.44) | NPY4RNPY1RNPY5RNPY2RMAPK8 | |
| SCHEMBL31480031 | 0.88 | MAPK8 (0.49) | NPY4RNPY1RNPY5RNPY2RMAPK8 | |
| SCHEMBL29496505 | 0.88 | PRCP (0.42) | NPY4RNPY1RNPY5RMAPK8MAPK9 | |
| SCHEMBL30416888 | 0.87 | MAPK8 (0.42) | NPY4RNPY1RNPY5RMAPK8MAPK9 | |
| SCHEMBL29437943 | 0.87 | MAPK8 (0.43) | NPY4RNPY1RNPY5RNPY2RMAPK8 | |
| SCHEMBL31195953 | 0.86 | MAPK8 (0.49) | NPY4RNPY1RNPY5RMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | NPY4R 599/4885NPY1R 352/4885NPY5R 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.